{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:40:56Z","timestamp":1784263256383,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The 2022 global mpox outbreak was notable for transmission between persons outside of travel and zoonotic exposures and primarily through intimate contact. An understanding of the presentation of mpox in people with human immunodeficiency virus (HIV) and other immunocompromising conditions and knowledge of the efficacy of tecovirimat continue to evolve.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study describes clinical features and outcomes of persons with mpox who received tecovirimat. Data were obtained via medical record review of patients prescribed tecovirimat in a health system in New York City during the height of the outbreak in 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred thirty people received tecovirimat between 1 July and 1 October 2022. People with HIV (n = 80) experienced similar rates of recovery, bacterial superinfections, and hospitalization compared to patients without immunocompromising conditions. Individuals determined to be severely immunocompromised (n = 14) had a higher risk of hospitalization than those without severe immunocompromise (cohort inclusive of those with well-controlled HIV, excluding those without virologic suppression, n = 101): 50% versus 9% (P &amp;lt; .001). Hospitalized patients (n = 18 [13% of total]) were primarily admitted for bacterial superinfections (44.4%), with a median hospital stay of 4 days. Of those who completed follow-up (n = 85 [66%]), 97% had recovery of lesions at time of posttreatment assessment. Tecovirimat was well tolerated; there were no reported severe adverse events attributed to therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There were no significant differences in outcomes between people with HIV when evaluated as a whole and patients without immunocompromising conditions. However, mpox infection was associated with higher rates of hospitalization in those with severe immunocompromise, including patients with HIV\/AIDS. Treatment with tecovirimat was well tolerated.<\/jats:p>\n                  <jats:p>Key Points: In our mpox cohort, people with HIV had similar rates of recovery and complications as those without HIV or other immunocompromising conditions. Severe immunocompromise was associated with a higher hospitalization rate. Tecovirimat was well tolerated, with minimal side effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofad552","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T19:38:23Z","timestamp":1699385903000},"source":"Crossref","is-referenced-by-count":11,"title":["Clinical Characteristics and Outcomes of Patients With Mpox Who Received Tecovirimat in a New York City Health System"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7278-8169","authenticated-orcid":false,"given":"Christopher","family":"Vo","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustin","family":"Zomorodi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Silvera","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Bartram","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz Amarilis","family":"Lugo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erna","family":"Kojic","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Landsp\u00edtali University Hospital , Reykjav\u00edk , Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Urbina","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Aberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-4861","authenticated-orcid":false,"given":"Keith","family":"Sigel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Chasan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopi","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , NewYork, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"2023113021481880300_ofad552-B1","article-title":"Mpox.","author":"World Health Organization","year":"2023"},{"key":"2023113021481880300_ofad552-B2","first-page":"593","article-title":"A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo","volume":"46","author":"Ladnyj","year":"1972","journal-title":"Bull World Health Organ"},{"key":"2023113021481880300_ofad552-B3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jama.279.3.189","article-title":"Human monkeypox\u2014Kasai Oriental, Democratic Republic of Congo, February 1996 October 1997","volume":"279","author":"Aplogan","year":"1998","journal-title":"J Am Med Assoc"},{"key":"2023113021481880300_ofad552-B4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.15585\/mmwr.mm6710a5","article-title":"Emergence of monkeypox\u2014West and Central Africa, 1970\u20132017","volume":"67","author":"Durski","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021481880300_ofad552-B5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.15585\/mmwr.mm7203a4","article-title":"Epidemiology of human mpox\u2014worldwide, 2018\u20132021","volume":"72","author":"McCollum","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021481880300_ofad552-B6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1056\/NEJMoa032299","article-title":"The detection of monkeypox in humans in the Western Hemisphere","volume":"350","author":"Reed","year":"2004","journal-title":"N Engl J Med"},{"key":"2023113021481880300_ofad552-B7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection in humans across 16 countries\u2014April\u2013June 2022","volume":"387","author":"Thornhill","year":"2022","journal-title":"N Engl J Med"},{"key":"2023113021481880300_ofad552-B8","first-page":"e26531","article-title":"Monkeypox: a comprehensive review of transmission, pathogenesis, and manifestation","volume":"14","author":"Kaler","year":"2022","journal-title":"Cureus"},{"key":"2023113021481880300_ofad552-B9","article-title":"WHO Director-General declares the ongoing monkeypox outbreak a public health emergency of international concern","author":"World Health Organization","year":"2022"},{"key":"2023113021481880300_ofad552-B10","article-title":"2022\u20132023 mpox outbreak global map","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2023113021481880300_ofad552-B11","article-title":"Mpox: 2022\u20132023 U.S. map and case count.","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2023113021481880300_ofad552-B12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.15585\/mmwr.mm715152a1","article-title":"Epidemiologic and clinical features of mpox in transgender and gender-diverse adults\u2014United States, May\u2013November 2022","volume":"71","author":"Blackburn","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021481880300_ofad552-B13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet"},{"key":"2023113021481880300_ofad552-B14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1473-3099(22)00806-4","article-title":"Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study","volume":"23","author":"Fink","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2023113021481880300_ofad552-B15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.7326\/M22-3132","article-title":"Tecovirimat treatment of people with HIV during the 2022 mpox outbreak: a retrospective cohort study","volume":"176","author":"McLean","year":"2023","journal-title":"Ann Intern Med"},{"key":"2023113021481880300_ofad552-B16","doi-asserted-by":"crossref","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","article-title":"The changing epidemiology of human monkeypox-A potential threat? A systematic review","volume":"16","author":"Bunge","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2023113021481880300_ofad552-B17","article-title":"2022\u201323 mpox (monkeypox) outbreak: global trends.","author":"World Health Organization","year":"2023"},{"key":"2023113021481880300_ofad552-B18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.15585\/mmwr.mm7144e1","article-title":"Severe monkeypox in hospitalized patients\u2014United States, August 10\u2013October 10, 2022","volume":"71","author":"Miller","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021481880300_ofad552-B19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023113021481880300_ofad552-B20","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.15585\/mmwr.mm7137e1","article-title":"Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol\u2014United States, May\u2013August 2022","volume":"71","author":"O\u2019Laughlin","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023113021481880300_ofad552-B21","article-title":"Guidance for tecovirimat use","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2023113021481880300_ofad552-B22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir Ther"},{"key":"2023113021481880300_ofad552-B23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2008.03.005","article-title":"Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model","volume":"79","author":"Nalca","year":"2008","journal-title":"Antivir Res"},{"key":"2023113021481880300_ofad552-B24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023113021481880300_ofad552-B25","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023113021481880300_ofad552-B26","doi-asserted-by":"crossref","first-page":"768","DOI":"10.4269\/ajtmh.2007.76.768","article-title":"Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection","volume":"76","author":"Sbrana","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2023113021481880300_ofad552-B27","article-title":"Expanded access IND protocol: use of tecovirimat (TPOXX) for treatment of human non-variola orthopoxvirus infections in adults and children","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"2023113021481880300_ofad552-B28","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023113021481880300_ofad552-B29","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"Jordan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023113021481880300_ofad552-B30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"2023113021481880300_ofad552-B31","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/jama.2022.15336","article-title":"Compassionate use of tecovirimat for the treatment of monkeypox infection","volume":"328","author":"Desai","year":"2022","journal-title":"JAMA"},{"key":"2023113021481880300_ofad552-B32","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.7326\/L22-0300","article-title":"Monkeypox virus\u2013associated severe proctitis treated with oral tecovirimat: a report of two cases","volume":"175","author":"Lucar","year":"2022","journal-title":"Ann Intern Med"},{"key":"2023113021481880300_ofad552-B33","doi-asserted-by":"crossref","first-page":"e01651","DOI":"10.1016\/j.idcr.2022.e01651","article-title":"Monkeypox and its broad clinical spectrum in immunocompromised patients: two case reports","volume":"31","author":"Mart\u00ednez","year":"2023","journal-title":"IDCases"},{"key":"2023113021481880300_ofad552-B34","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S0140-6736(22)01528-8","article-title":"Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat","volume":"400","author":"Hernandez","year":"2022","journal-title":"Lancet"},{"key":"2023113021481880300_ofad552-B35","article-title":"Characterization of mpox in people who live with HIV: a country-wide observational study [Poster Presentation]","author":"N\u00fa\u00f1ez","year":"2023"},{"key":"2023113021481880300_ofad552-B36","article-title":"HIV surveillance annual report, 2021","author":"New York City Department of Health and Mental Hygiene","year":"2021"},{"key":"2023113021481880300_ofad552-B37","article-title":"HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022.","author":"Hoxha","year":"2023"},{"key":"2023113021481880300_ofad552-B38","article-title":"Early clinical experience using tecovirimat during the Mpox epidemic in Toronto suggests ongoing clinical equipoise for randomized trials","author":"Shah","year":"2023","journal-title":"International AIDS Society Conference"},{"key":"2023113021481880300_ofad552-B39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3201\/eid2905.221797","article-title":"Mpox among public festival attendees, Chicago, Illinois, USA, July\u2013August 2022","volume":"29","author":"Faherty","year":"2023","journal-title":"Emerg Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad552\/52789793\/ofad552.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad552\/53899123\/ofad552.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/11\/ofad552\/53899123\/ofad552.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T21:48:51Z","timestamp":1701380931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad552\/7338856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad552","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11,1]]},"article-number":"ofad552"}}